Introduction: Chronic respiratory conditions, especially chronic obstructive pulmonary disease (COPD), and inflammatory events underlie lung cancer (LC). We hypothesized that profiles of T helper 1 and T helper 2 cytokines and type 1 and type 2 macrophages (M1 and M2) are differentially expressed in lung tumors and blood of patients with NSCLC with and without COPD and that the ratio M1/M2 specifically may influence their survival.
Introduction
In cancer-related mortality, lung cancer (LC) continues to be the most common cause of death worldwide, [1] [2] [3] [4] [5] accounting for almost one-third of deaths in certain regions. 6 Underlying respiratory conditions such as chronic obstructive pulmonary disease (COPD), which is also a highly prevalent disorder in industrialized countries, has been consistently associated with LC occurrence. [7] [8] [9] [10] [11] Airway obstruction and emphysema are, indeed, important risk factors for LC. [7] [8] [9] [10] [11] The biological mechanisms that render patients with chronic lung diseases more susceptible to LC development remain to be fully elucidated.
In this regard, despite the complex interactions observed among inflammation, immunity, and lung tumor development, chronic inflammation has already been identified as a potential trigger in the process of tumorigenesis. As such, chronic inflammatory insults in the airways and lungs of respiratory patients may favor the risk for LC, as has also been shown to occur in other cancer types such as pancreatic, esophageal, and stomach. [12] [13] [14] In this regard, induction of several interleukins (ILs) and cyclooxygenase-2 activity was suggested to contribute to the neoplastic transformation in patients with COPD. [15] [16] [17] Importantly, those inflammatory molecules may interfere with regulatory cell mechanisms such as repair, angiogenesis, and apoptosis, which favor the neoproliferative process. [15] [16] [17] Furthermore, cytokines and growth factors such as tumor necrosis factor-a (TNF-a), IL-2, IL-4, IL-10, vascular endothelial growth factor (VEGF), transforming growth factor-b (TGF-b), and EGFR have also been shown to promote tumor growth and metastasis in patients with underlying respiratory conditions. [18] [19] [20] [21] [22] Tumor immune surveillance also seems to play an important role in LC development, including in patients with chronic respiratory diseases. 23 Interestingly, T helper 1 (Th1) lymphocytes, which release TNF-a, IL-2, and interferon-g (IFN-g), exert antitumor effects, whereas T helper 2 (Th2) cells, which mainly produce IL-4, were shown to favor tumor growth by inhibiting the host immune system. 24 Tumorigenesis and relapse may rely on alterations in Th1 and Th2 cytokines in patients. 20, 25, 26 In line with this, in patients with LC, systemic Th2 cytokine levels were increased, whereas those of Th1 were decreased. 20 Importantly, a change in Th1 and Th2 cytokines was seen in the same patients after surgical treatment of their lung tumor, suggesting that these cytokines may play a significant role in tumor progression. 20 In tumor microenvironment, type 1 (M1) and type 2 (M2) polarized macrophage subtypes play a role in tumorigenesis through the regulation of several functions such as cell adhesion, apoptosis, and senescence. [25] [26] [27] Furthermore, M1 macrophages were shown to act in the initial process of tumorigenesis, exerting antitumorigenic effects, whereas M2 macrophages were the predominant cells of established tumors. 28 Besides, decreased M1/M2 macrophages may also influence tumor survival. 29 Whether the pattern of chronic inflammatory events including the subtypes of macrophages may differ in the tumors of patients with LC with underlying respiratory diseases such as COPD remains an open question. Answers to these questions may offer insight that may help in design of immunotherapeutic strategies for the better management of LC.
On this basis, we hypothesized that Th1 and Th2 cytokine profiles and M1 and M2 macrophages are differentially expressed in the lung tumor and nontumor parenchyma and blood of patients with LC with and without COPD and that, specifically, the M1/M2 ratio may influence their survival. Hence, the study objectives were to determine: (1) protein levels of Th1 and Th2 cytokines and (2) M1 and M2 macrophage counts in the lung in plasma, tumor lesions, and nontumor lung of patients with NSCLC with and without underlying COPD and (3) survival of patients according to numbers of M1 and M2 macrophages.
Methods
See the Supplementary Data for detailed information on all methods, including statistical analysis.
Study Design and Patient Recruitment
This is a prospective, cross-sectional study in which patients were recruited consecutively from the Lung Cancer Clinic of the Respiratory Medicine Department at Hospital del Mar (Barcelona, Spain). For purposes of the investigation, 80 white patients with LC were recruited consecutively before receiving any treatment for their lung neoplasm from the weekly LC board meeting. Blood samples were obtained at the time of diagnostic confirmation of LC in all 80 patients. These patients were further subdivided post hoc into two groups according to the presence of underlying COPD, which was diagnosed on the basis of current guidelines [30] [31] [32] [33] : (1) 60 patients with LC who also had COPD (the LC-COPD group, which included one female patient) and (2) 20 patients with LC without COPD (the LC-only group, which included seven female patients). Fifty-seven male patients and one female patient in the LC-COPD group and 13 male and seven female patients in the LC-only group simultaneously participated in a previous study aimed at assessing redox balance in lung tumors. 34 Moreover, from the same study cohort, in the group of patients who underwent thoracotomy for surgical resection of their lung neoplasms (clinical indication according to guidelines for diagnosis and management of lung cancer), [30] [31] [32] [33] specimens from the tumor and nontumor lung parenchyma were also obtained in all cases (n ¼ 40) and were further subdivided post hoc as follows: (1) 20 patients in the LC-COPD group (all male) and (2) 20 patients in the LC-only group (including seven female patients). Therefore, in these two groups of patients (LC-only and LC-COPD), blood and lung specimens were available for the study. Twenty male patients in the LC-COPD group as well as eight male and four female patients in the LC-only group also participated in the previous study. 34 Histological diagnosis and TNM staging of LC were confirmed in all patients. [30] [31] [32] [33] Exclusion criteria were as follows: SCLC, chronic cardiovascular, chronic metabolic and clot system disorders, signs of severe bronchial inflammation and/or infection (bronchoscopy), current or recent invasive mechanical ventilation, and chronic oxygen therapy. 
Clinical Assessment
Lung function parameters were assessed in all patients in accordance with standard procedures. Evaluation of body composition included assessment of body mass index and fat-free mass index by bioelectrical impedance. Nutritional parameters were also evaluated through conventional blood tests.
Sample Collection
Blood sample specimens were obtained in all the recruited patients (n ¼ 80) from the arm vein after an overnight fasting period. Moreover, in all patients undergoing thoracotomy (n ¼ 40), lung specimens were obtained from both tumor and nontumor surrounding parenchyma during the operation, during which standard technical procedures were followed by the specialized thoracic surgeons. The expert pathologist selected a fragment of lung tumor and nontumor specimens with a size of approximately 10 Â 10 mm 2 from the fresh samples after careful collection of the specimens required for diagnostic purposes.
Sample Preservation
Lung specimens were immediately frozen in liquid nitrogen and stored in a -80 C freezer (under permanent alarm control) for further analysis or immersed in an alcohol-formol bath to be embedded in paraffin. Blood samples were centrifuged and frozen at À80 C until further analyses. Frozen tissues were used for enzymelinked immunosorbent assay (ELISA) techniques, and paraffin-embedded lung sections, which were generously provided by MAR Health Park Biobank (MARBiobanc, Barcelona), were used for the assessment of macrophage counts (immunohistochemical analyses).
Molecular Biology Analyses
Quantification of Cytokines and Growth Factors in Plasma by ELISA. Protein levels of TNF-a, VEGF, IL-2, IL-10, IFN-g, TGF-b, and IL-4 were quantified in blood (plasma) from all patients by using ELISA kits (Gen-probe Diaclone SAS, Besançon, France) following previous studies. 15, 35, 36 Quantification of Cytokines and Growth Factors in Lung Tissue (Tumor and Nontumor) by ELISA. Protein levels of TNF-a, VEGF, IL-2, IL-10, IFN-g, EGFR, TGF-b, and IL-4 were quantified in lung specimens from all patients with ELISA kits (Raybiotech Inc., Norcross, GA, and Cloud-Clone Corp, Houston, TX), following previous studies. 15, 35, 36 Counts and Types of Macrophages in Lung Specimens (Tumor and Nontumor). M1 and M2 macrophages were identified on 3-mm paraffin-embedded lung sections by using double-staining immunohistochemical procedures (Envision DuoFLEX Doublestain System, Dako North America, Inc., Carpinteria, CA) following the manufacturer's instructions and previous studies.
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Statistical Analyses
All statistical analyses were performed using the SPSS 15.0 software (SPSS, Inc, Chicago, IL). Data were expressed as means and SD. The normality of the study variables was explored using the Shapiro-Wilk test. To test the potential effects of cigarette smoking on the study results, the LC-COPD group was further subdivided into moderate (n ¼ 25) and heavy (n ¼ 35) smokers, with 60 pack-years serving as the cutoff value (median). On the basis of a standard power statistics established at a minimum of 80% and with assumption of an a error of 0.05, the statistical power was sufficiently high to detect minimum differences between the two study groups in the target variables (plasma cytokines and macrophage subtypes). The sample size was calculated on the basis of these parameters, which required a minimum of 40 to 50 patients for the plasma cytokine analyses and 15 patients for the analyses conducted on the lung specimens to detect potential differences in the study variables between the two groups.
Between-group differences in the study variables were assessed by using one-way analysis of variance, and Tukey's post hoc analysis was used to adjust for multiple comparisons. Differences between study groups for qualitative variables were explored using the chi-square test. Statistical significance was established at p values of 0.05 or less. Variables from the two compartments (blood and lungs) were evaluated independently.
Results
Clinical Characteristics
Clinical and functional characteristics of all patients in the LC-COPD and LC-only groups who were recruited in the study are shown in Tables 1 and 2 (all patients as a group and only patients undergoing thoracotomy, respectively). The number of patients in the LC-COPD group was higher than the number in the LC-only (25) 9 (15) 5 (20) 
3 (15) 9 (15) 3 (12) 6 (17) Stage IIIB, n (%)
4 (20) 7 (12) 1 (4) 6 (17) Stage IV, n (%)
3 (15) 16 (27) 7 (28) 9 (25) Histological diagnosis Squamous cell carcinoma, n (%) 6 (30) 27 (45) 12 (48) 15 (43) Adenocarcinoma, n (%)
11 (55) 24 (40) 10 (40) 14 (40 (6) e Note: Comparisons of the clinical and physiological variables between the LC-COPD group and the LC-only group, as well as between the two groups of patients in the LC-COPD group (moderate and heavy smokers), were assessed using Student's t test. Differences between the study groups for the qualitative variables were assessed using the chi-square test. a p 0.05 between patients in the LC-COPD group and patients in the LC-only group. b p 0.01 between patients in the LC-COPD group and patients in the LC-only group. c p 0.001 between patients in the LC-COPD group and patients in the LC-only group. d p 0.01 between heavy and moderate smokers in the LC-COPD group in the post hoc analyses. e p 0.001 between heavy and moderate smokers in the LC-COPD group in the post hoc analyses. LC, lung cancer; COPD, chronic obstructive pulmonary disease; BMI, body mass index; FEV 1 , forced expiratory volume in the first second; pred, predicted; FVC, forced vital capacity; DLCO, carbon monoxide transfer; KCO, Krogh transfer factor; CRP, C-reactive protein; GSV, globular sedimentation velocity.
group, and there were mostly male patients in both groups (see Tables 1 and 2 ). No significant differences were found in age or body mass index between patients in the LC-COPD and LC-only groups (see Tables 1 and 2 ).
Smoking history differed between patients in the LC-COPD and LC-only groups (see Table 1 ). The functional parameters diffusion lung capacity for carbon monoxide, forced expiratory volume in 1 second, and ratio of forced 
Note: Continuous variables are presented as mean (standard deviation), whereas categorical variables are presented as the number of patients in each group and percentage of the total population. Comparisons of the clinical and physiological variables between LC-COPD as a group and LC-only patients, as well as between the two groups of LC-COPD patients (moderate and heavy smokers) were assessed using Student's t test. Differences between the study groups for the qualitative variables were assessed using the chi-square test. a p 0.05 between patients in the LC-COPD group and patients in the LC-only group. expiratory volume in 1 second to forced vital capacity were significantly decreased in the LC-COPD group compared with in patients in the LC-only group (see Tables 1 and 2 ). No significant differences were found in these parameters between heavy and moderate smokers within the LC-COPD group (see Tables 1 and 2) . Moreover, no statistically significant differences were found in either TNM or histological subtypes between the Figure 1 . (A) Mean values and SD of blood tumor necrosis factor-a (TNF-a) levels are shown in the graph. As described in Methods, comparisons were made between the lung cancer-only (LC-only) and LC-chronic obstructive pulmonary disease (LC-COPD) groups; among the latter patients, analyses were also made between heavy and moderate smokers. TNF-a levels were significantly higher in LC-COPD group than in patients in the LC-only group. Levels of TNF-a did not differ significantly between heavy and moderate smokers. (B) Mean values and SD of blood interleukin-2 (IL-2) levels are shown in the graph. As described in Methods, comparisons were made between the LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. IL-2 levels were significantly increased in the LC-COPD group compared with in patients in the LC-only group. IL-2 levels were also higher in heavy smokers than in moderate smokers in the LC-COPD group. (C) Mean values and SD of blood interferon-g (IFN-g) levels are shown in the graph. As described in Methods, comparisons were made between LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. IFN-g levels did not differ significantly among the study groups. (D) Mean values and SD of blood vascular endothelial growth factor (VEGF) levels are shown in the graph. As described in Methods, comparisons were made between the LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. VEGF levels were significantly decreased in patients in the LC-COPD group compare with in those in the LC-only group. Levels of VEGF did not differ significantly between heavy and moderate smokers. (E) Mean values and SD of blood IL-4 levels are shown in the graph. As described in Methods, comparisons were made between the LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. IL-4 levels were significantly reduced in the LC-COPD group compared with in the LC-only group. Levels of IL-4 did not differ significantly between heavy and moderate smokers. (F) Mean values and SD of blood transforming growth factor-b (TGF-b) levels are shown in the graph. As described in Methods, comparisons were made between the LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. Levels of TGF-b were significantly higher in LC-COPD than in LC patients. Levels of TGF-b did not differ significantly between heavy and moderate smokers. (G) Mean values and SD of blood interleukin-10 (IL-10) levels are shown in the graph. As described in Methods, comparisons were made between the LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. IL-10 levels were significantly increased in patients in the LC-COPD group compared with in patients in the LC-only group. Levels of IL-10 did not differ significantly between heavy and moderate smokers. Tables 1 and 2 ). In the LC-COPD group compared with in patients in the LC-only group, levels of albumin and fibrinogen were decreased, whereas C-reactive protein level and globular sedimentation velocity were increased (see Tables 1 and 2) . Furthermore, body weight loss was greater in patients in the LC-COPD group, especially in heavy smokers, compared with in patients in the LC-only group (see Table 1 ).
LC-COPD and LC-only groups (see
Systemic Levels of Cytokines
In patients in the LC-COPD group, levels of TNF-a and IL-2 levels were higher than in patients in the LC-only group (Fig. 1A and B) . Systemic levels of IFN-g did not differ among the study groups (Fig. 1C) . In the post hoc analyses, levels of IL-2 were higher in heavy smokers than in moderate smokers, whereas no differences were observed in either TNF-a or IFN-g levels between these groups (Fig. 1A-C) . In patients in the LC-COPD group, levels of VEGF and IL-4 were significantly lower, whereas those of TGF-b and IL-10 were higher than in patients in the LC-only group (Fig. 1D-G) . Levels of the cytokines VEGF, IL-4, TGF-b, and IL-10 did not differ between heavy and moderate smokers in patients in the LC-COPD group (Fig. 1D-G) . No significant associations were found between systemic levels of the study cytokines and the patients' survival (data not shown).
Levels of Cytokines and Growth Factors in the Lung Specimens
Tumor versus Nontumor Parenchyma in Patients in the LC-COPD and LC Groups. In patients in the LC-COPD group and especially in moderate smokers, TNF-a levels were significantly increased in tumor lesions compared with in nontumor specimens, whereas no differences were seen in patients in the LC-only group ( Fig. 2A) . IL-2 levels were significantly higher in tumor lesions of patients in both the LC-only and LC-COPD groups compared with in nontumor specimens (Fig. 2B) . No differences were found in IFN-g levels between lungs with and without tumors in any of the study groups (Fig. 2C) . VEGF levels were significantly higher in tumor lesions than in the nontumor lungs in all patients in the LC-COPD and LC-only groups ( Figure 2D ). In the latter patients, levels of TGF-b were increased in tumor Mean values and SD of lung tumor necrosis factor-a (TNF-a) levels are depicted in the graph. As described in Methods, comparisons were made between the lung cancer-only (LC-only) and LC-chronic obstructive pulmonary disease (LC-COPD) groups; among the latter patients, analyses were also made between heavy and moderate smokers. Moreover, TNF-a levels detected in nontumor (NT) and tumor (T) lungs are also represented in graphs for all the groups for purposes of comparison. Levels of TNF-a were significantly higher in the T lesions compared with in NT lungs in the LC-COPD group, especially in moderate smokers. TNF-a levels did not differ significantly between T and NT in patients in the LC-only group or between those in the LC-COPD and LC-only groups. No significant differences were found in TNF-a levels between heavy and moderate smokers in either T or NT lungs. (B) Mean values and SD of lung interleukin-2 (IL-2) levels are depicted in the graph. As described in Methods, comparisons were made between the LC-only and LC-COPD groups, and among the latter patients, analyses were also made between heavy and moderate smokers. Moreover, IL-2 levels detected in NT and T lungs are also represented in graphs for all the groups for the purpose of comparison. Levels of IL-2 were significantly higher in T lesions compared with in NT lung specimens in patients in both the LC-only and LC-COPD groups. IL-2 levels did not differ significantly between patients in the LC-COPD and LC-only groups or between moderate and heavy smokers. (C) Mean values and SD of lung interferon-g (IFN-g) levels are depicted in the graph. As described in Methods, comparisons were made between the LConly and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. Moreover, IFN-g levels detected in NT and T lungs are also represented in graphs for all the groups for purposes of comparison. IFN-g levels did not differ significantly in any of the study groups of patients. (D) Mean values and SD of lung vascular endothelial growth factor (VEGF) levels are depicted in the graph. As described in Methods, comparisons were made between the LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. Moreover, VEGF levels detected in NT and T lungs are also represented in graphs for all the groups for purposes of comparison. Levels of VEGF were significantly increased in T lesions compared with in NT lung specimens in patients in both the LC-only and LC-COPD groups, especially in heavy and moderate smokers. Lung VEGF levels were also higher in the T lesions of patients in the LC-COPD group than in those in the LC-only group. No significant differences were found between heavy and moderate smokers. (E) Mean values and SD of lung transforming growth factor-b (TGF-b) levels are depicted in the graph. As described in Methods, comparisons were made between patients in the LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. Moreover, TGF-b levels detected in NT and T lungs are also represented in graphs for all the groups for purposes of comparison. Levels of TGF-b were significantly higher in T lesions than in NT lung specimens of patients in the LC-COPD group. TGF-b levels were also increased in T lesions of those in the LC-COPD group compared with in patients in the LC-only group. No significant differences were found between T and NT lung specimens in patients in the LC-only group or between heavy and moderate smokers. (F) Mean values and SD of lung interleukin-4 (IL-4) levels are depicted in the graph. As described in Methods, comparisons were made between patients in the LC-only and lesions compared with in nontumor specimens (Fig. 2E) . No differences were found in IL-4 levels between tumor and nontumor lungs in any of the study patient groups (Fig. 2F) . In all patients in the LC-COPD group, IL-10 levels were higher in the tumors than in the lungs without a tumor (Fig. 2G) . In both groups of patients, EGFR levels were significantly increased in tumor specimens compared with in nontumor lesions (Fig. 2H) , and no differences were seen between moderate and heavy smokers. Finally, no significant correlations were found in any of the study cytokines between blood and lung compartments.
Differences between the LC-COPD and LC-Only Groups in Either Tumor Lesions or Nontumor
Specimens. No significant differences were found in TNF-a, IL-2, and IFN-g levels between patients in the LC-COPD group (both heavy and moderate smokers) and those in the LC-only group in either tumor or nontumor lungs ( Fig. 2A-C) . In patients in the LC-COPD group LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. Moreover, IL-4 levels detected in NT and T lungs are also represented in graphs for all the groups for purposes of comparison. Levels of IL-4 did not differ significantly among the study groups of patients. (G) Mean values and SD of lung interleukin-10 (IL-10) levels are depicted in the graph. As described in Methods, comparisons were made between patients in the LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. Moreover, IL-10 levels detected in NT and T lungs are also represented in graphs for all the groups for purposes of comparison. Levels of IL-10 were significantly higher in T lesions compared with in NT lung specimens in patients in the LC-COPD group, especially in moderate and heavy smokers. IL-10 levels were also increased in T parenchyma of those in the LC-COPD group compared with in patients in the LC-only group. No significant differences were found between T and NT in patients in the LC-only group or between heavy and moderate smokers. (H) Mean values and SD of lung EGFR levels are depicted in the graph. As described in Methods, comparisons were made between patients in the LC-only and LC-COPD groups; among the latter patients, analyses were also made between heavy and moderate smokers. Moreover, EGFR levels detected in NT and T lungs are also represented in graphs for all the groups for purposes of comparison. Levels of EGFR were significantly higher in T lesions compared with in NT lung specimens in patients in both the LC-only and LC-COPD groups. No significant differences were observed in EGFR levels between patients in the LC-COPD and LC-only groups or between heavy and moderate smokers.
compared with in patients in the LC-only group, levels of VEGF, TGF-b, and IL-10 were higher in the tumor lesions (Fig. 2D , E, and G). Levels of IL-4 did not differ significantly between patients in the LC-COPD and LC-only groups in either tumor or nontumor lungs (Fig. 2F) . No significant differences were found in VEGF, TGF-b, IL-4, IL-10, or EGFR levels between moderate and heavy smokers within the LC-COPD group of patients ( Fig. 2D-H) . No significant associations were found between lung levels of the study cytokines or growth factors and the patients' survival (data not shown).
M1 and M2 Macrophage Subtypes in the Lung. In both the LC-COPD and LC-only groups, levels of M2 macrophages were increased, whereas the level of M1 macrophages and the M1/M2 ratio were decreased in lung tumors compared with in nontumor specimens (Fig. 3A-B and Table 3 ). In tumor specimens, the M1/M2 ratio was significantly higher in the LC-COPD group than in the LC-only group (Table 3) . No significant associations were found between M1 level, M2 level, or M1/M2 ratio and patients' survival in any study group ( Supplementary  Fig. 1A and B) .
Discussion
In the current study, the main findings were that patients with LC and COPD exhibited a moderate airway obstruction and functional emphysema; adenocarcinoma was the predominant histological type, and those who smoked more showed a significantly greater loss of body weight. Moreover, in patients in the LC-COPD group compared with those in the LC-only group, systemic levels of the Th1 cytokines TNF-a, IL-2 and those of the Th2 cytokines TGF-b and IL-10 were increased, whereas those of VEGF and IL-4 were decreased, with no significant differences in IFN-g levels. In patients in the LC-COPD group, levels of TNF-a, TGF-b, and IL-10 were higher in tumors than in nontumor lungs, whereas a significant rise in IL-2 and VEGF levels was seen in the tumors of both groups. Moreover, VEGF, TGF-b, and IL-10 levels were higher in the tumors of patients in the LC-COPD group than in patients in the LC-only group. In the tumors of both groups, the level of M1 macrophages and the M1/M2 ratio were reduced, whereas the M1/M2 ratio was significantly higher in patients in the LC-COPD group. Smoking history did not influence the differences in study parameters between groups. Importantly, no correlations between lung and blood compartments were observed for any of the study variables in the two groups of patients. In view of these findings, the study hypothesis was confirmed to a great extent. CD4-positive T lymphocytes are divided into Th1 and Th2 cells on the basis of the secreted cytokines. Th1 lymphocytes release TNF-a, IL-2, and IFN-g, which exert antitumor effects in humans, whereas Th2 cells produce IL-4 and IL-10, which favor tumor growth by inhibiting the host immune system. 24, 25 In patients with several types of cancer, alterations of the Th1/Th2 immunological balance have been detected in tumorigenesis and cancer relapse. 20, 25, 26 In the present investigation, systemic levels of TNF-a, IL-2, TGF-b, and IL-10 were significantly increased in patients with underlying COPD compared with in those without any respiratory condition. These findings suggest that Th1 systemic immunological response and regulatory T-lymphocyte cytokines (TGF-b and IL-10) were significantly enhanced in patients with the two conditions COPD and LC. It is likely that in COPD systemic inflammation as a result of chronic exposure to cigarette smoke drives a general Th1 response in the patients that is not observed in patients with LC without COPD.
Importantly, in the lung tumors of patients with LC and underlying COPD, levels of the cytokines TNF-a, TGF-b, and IL-10 were significantly higher than those encountered in the surrounding nontumor lung. Moreover, levels of VEGF, TGF-b, and IL-10 were also significantly higher in the tumors of patients in the LC-COPD group than in patients in the LC-only group. Interestingly, levels of IL-4 did not differ in lung specimens among the study groups. Collectively, these findings suggest that in COPD, chronic inflammation in the lungs is characterized by the release of Th1 and regulatory T lymphocytes, which may protect patients against tumor development and progression. Indeed, similar findings were reported in the bronchial epithelium of patients with LC and COPD. 15 Nonetheless, a previous study 20 showed that in patients with NSCLC, systemic levels of Th2 cytokines were increased, whereas those of Th1 cytokines were reduced compared with the levels in healthy subjects. In the same investigation, 20 patients with NSCLC were shown to have lower systemic Th2 cytokine levels in response to lung tumor resection, and the relapse rates were significantly higher in those patients with persistent abnormal levels of IL-4. Importantly, in that study 20 patients were not analyzed according to the presence of COPD or smoking history. In fact, this analysis is a major novel contribution of the current investigation.
EGFR is the cell surface receptor of the epidermal growth factor family of protein ligands in several cell types that contribute to the correct development of glands in tissues. Mutations of EGFR that induce its overexpression are involved in tumorigenesis such as LC. Despite the fact that the efficacy of anti-EGFR therapies (namely EGFR tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies) remains controversial in certain types of NSCLC, especially squamous LC, beneficial effects have been observed in recent studies in which adenocarcinoma was the predominant histological subtype. 40, 41 Moreover, durable clinical responses beyond 5 years have also been proposed in response to pathway-targeted immunotherapy as a result of treatment of patients with NSCLC with a novel epidermal growth factor-directed agent. 42 As in previous studies, 40, 41, 43 in the present investigation, in both groups of patients, EGFR levels were also significantly higher in the tumor lesions than in the surrounding nontumor parenchyma. Identification of potential mutations of EGFR gene, however, was beyond the scope of the current study and will remain the focus of research in future investigations.
Macrophages may exert proinflammatory or antiinflammatory functions depending on the secreted cytokines. In tumors, the inflammatory infiltrates are mostly represented by this type of cells. In general, M1 macrophages favor inflammation, whereas M2 macrophages promote anti-inflammatory actions and tissue repair. Whereas M1 cells fight against tumor development, M2 macrophages exert the opposite effects by promoting cancer growth, survival, progression, and dissemination. 25 In keeping with this, in the tumor lesions of both study groups of patients, the number of M1 macrophages was reduced whereas the number of M2 was increased. Hence, the ratio of M1 to M2 cells was also significantly lower in the tumors than in the surrounding nontumor lung in all groups of patients. Indeed, interaction of factors such as the stage of the tumor and the local microenvironment has been shown to determine macrophage phenotype and tumor progression. 25 Importantly, in the study, tumors of LC patients with underlying COPD exhibited a significantly higher M1/M2 ratio than those of patients without COPD. These results suggest that the relative predominance of the M1 phenotype in tumors of patients with LC and COPD may imply a better prognosis in such patients compared with in those with no COPD. Nonetheless, the number of macrophages or M1/M2 ratio was not associated with patients' survival in any of the study groups (see Supplementary Fig. 1A and B) , as was shown to occur in other types of tumors. 29 It is likely that the statistically significant difference of M1/M2 ratio in tumors between the two study groups may not be of sufficient biological relevance to modify the prognosis of patients with LC.
Importantly, in the last few years, a better and progressive understanding of the complex interactions between the immune system, inflammation, and carcinogenesis, including in LC treatment, has led to the development of novel immunotherapeutic agents. 44, 45 Nonetheless, the efficacy of these immunomodulatory drugs is hampered by the acquired resistance after certain periods of time. 44, 45 Hence, further insight into the potential contribution of the immune system to lung carcinogenesis is required to design immunotherapeutic strategies that will ensure longer-lasting control of the disease. Cytokines, monoclonal antibodies, tumor and dendritic cell vaccines, and checkpoint inhibitors are examples of the passive and active immunotherapy agents that are currently used in clinical settings. [44] [45] [46] Future research in this field will shed light onto further mechanisms that will selectively target tumor cells in patients with LC.
Study Limitations
The first limitation in the study is the relatively lower number of lung specimens analyzed in the study compared with the number of blood samples. Nevertheless, for ethical reasons, tumor and nontumor lung specimens could be obtained only from patients undergoing thoracotomy for the treatment of their lung neoplasm from the established cohort of patients who participated in this investigation, from whom blood samples had been collected. Furthermore, the study variables could have also been analyzed by using other approaches in which the potential predictive value of the analyzed markers may have been estimated. However, the investigation was aimed at identifying whether underlying COPD influences the expression of Th1 and Th2 cytokines in patients with LC. Another approach would be to analyze the expression of the target variables on the basis of histological subtypes. In this regard, no significant differences were detected in any of the clinical or biological variables between the two groups.
Another limitation is the relatively low numbers of female patients in both groups. This is because the prevalence of LC in female patients, especially among those patients with underlying COPD, is still very low in our geographical region. 7, 9, 10 Despite these limitations, the main findings confirmed the study hypothesis to a great extent.
Conclusions
A differential expression profile of inflammatory markers and cells has been identified in the lung tumors and blood compartment in patients with LC who have a chronic respiratory condition, irrespective of smoking history. The relative predominance of Th1 cytokines and M1 macrophages in the blood and tumors of patients with underlying COPD implies that a stronger proinflammatory pattern exists in these patients. These findings have potential clinical implications, as inflammation should not be targeted systematically in all patients with LC. Screening for the presence of underlying respiratory diseases and identification of the specific inflammatory pattern should be carried out in patients with LC, at least in early stages of their disease.
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